Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Eli Lilly is going to test Zepbound as a treatment for addiction
Quartz
Wednesday, December 11, 2024 - 10:44pm
tags:
Eli Lilly, David Ricks, Zepbound, addiction, alcohol-use disorder
New bipartisan legislation would force insurers, PBMs to sell pharmacy businesses
Healthcare Dive
Wednesday, December 11, 2024 - 10:41pm
tags:
legistation, PBMs, CVS Health, Cigna, UnitedHealth
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
Wednesday, December 11, 2024 - 11:40am
tags:
Gilead Sciences, Biktarvy, patent cliffs, HIV
Walgreens shares surge on reported talks to be taken private
Axios
Wednesday, December 11, 2024 - 11:31am
tags:
Walgreens, pharmacies, private equity
How the Omnicom-IPG merger could reshape pharma marketing
Medical Marketing and Media
Wednesday, December 11, 2024 - 11:29am
tags:
pharma marketing, Omnicom, IPG, M&A
How Trump’s second term will affect the medtech industry
Medtech Dive
Wednesday, December 11, 2024 - 11:28am
tags:
Medtech, Donald Trump, tarriffs, M&A, CDRH, LDTs
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
Fierce Biotech
Wednesday, December 11, 2024 - 11:27am
tags:
AnaptysBio, clinical trials, eczema, atopic dermatitis, ANB032
ASH 2024: Merck’s new ADC posts positive results in first-line DLBCL
Clinical Trials Arena
Wednesday, December 11, 2024 - 11:21am
tags:
ASH 2024, Merck, clinical trials, DLBCL, zilovertamab vedotin
Candel Therapeutics stock up 172% after Phase III prostate cancer success
Clinical Trials Arena
Wednesday, December 11, 2024 - 11:19am
tags:
Candel Therapeutics, clinical trials, prostate cancer, CAN-2409
BenevolentAI restructures
BioPharma Dive
Wednesday, December 11, 2024 - 11:17am
tags:
BenevolentAI, restructuring, artificial intelligence
Jury convicts ex-CytoDyn CEO on 9 counts tied to biotech fraud
Fierce Biotech
Wednesday, December 11, 2024 - 11:02am
tags:
legal, CytoDyn, biotech, fraud, Maryland
Lilly to offer single-dose vials of weight-loss drug on telehealth platform Ro
Yahoo Finance
Wednesday, December 11, 2024 - 11:01am
tags:
Eli Lilly, Ro, telehealth, Zepbound
Can CAR-T first movers keep pace in a rapidly evolving market?
Pharmaphorum
Wednesday, December 11, 2024 - 10:59am
tags:
CAR-T, Gilead Sciences, Novartis
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
BioPharma Dive
Tuesday, December 10, 2024 - 10:11pm
tags:
NewAmsterdam Pharma, obicetrapib, CETP inhibitors
Pharma, life sciences execs ‘optimistic’ for 2025, eye regulatory concerns
Medical Marketing and Media
Tuesday, December 10, 2024 - 10:07pm
tags:
pharma industry, regulatory
CSL Vifor floats £23M offer, doctor outreach campaign in bid to resolve UK antitrust probe
Fierce Pharma
Tuesday, December 10, 2024 - 10:05pm
tags:
CSL Vifor, physicians, UK, pharma marketing, antitrust
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Drugs.com
Tuesday, December 10, 2024 - 10:02pm
tags:
Novavax, clinical trials, COVID-19, Flu, vaccines
Roche said it didn’t want to buy Poseida last year: A look at how the $1.5B buyout came to be
Fierce Biotech
Tuesday, December 10, 2024 - 10:00pm
tags:
Roche, Poseida Therapeutics, M&A, cell therapy
Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump
MSN/Reuters
Tuesday, December 10, 2024 - 9:58pm
tags:
Eli Lilly, David Ricks, Pharma CEOs, Donald Trump, taxes, regulatory
BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer
Fierce Biotech
Tuesday, December 10, 2024 - 11:42am
tags:
BioNTech, breast cancer, clinical trials, BNT327, Merck, Keytruda

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.